The loss of patent protection on Amarin’s sole commercial product Vascepa in 2020 has led to a roller coaster ride for the Dublin-based company over the past few years.
But, now, the dr-gmaker is getting a fresh shot to challenge Hikma Pharmaceuticals’ generic version of its fish-oil-derived heart med in the lower courts.
Tuesday, the U.S. Court of Appeals for the Federal Circuit revived Amarin’s Vascepa patent lawsuit against generics giant Hikma.
“Because Amarin’s allegations against Hikma plausibly state a claim for induced infringement, we reverse,” the court wrote in a legal filing this week.
https://www.fiercepharma.com/pharma/amarin-wins-bid-revive-vascepta-patent-lawsuit-against-hikma